RadNet to Acquire iCad in $103 Million All-Stock Deal

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

RadNet to Acquire iCad in $103 Million All-Stock Deal

, MT Newswires - 4:29 PM ET 4/15/2025 Company News

04:29 PM EDT, 04/15/2025 (MT Newswires) -- RadNet ( RDNT ) has agreed to acquire iCad (ICAD) in an all-stock deal valued at roughly $103 million, the companies said late Tuesday.

Shares of iCad jumped more than 72% in recent after-hours activity, while those of RadNet ( RDNT ) were down 2%.

As part of the agreement, iCad shareholders will receive 0.0677 shares of RadNet ( RDNT ) common stock for each iCad share they own, valuing it at $3.61 per share, a 98% premium based on the closing prices Monday.

The acquisition is expected to merge advanced artificial intelligence technologies from both companies to strengthen early breast cancer detection and streamline diagnostic workflows, the companies said.

The transaction, unanimously approved by both companies' boards, is expected to close in Q2 or Q3, pending iCad stockholder approval and customary closing conditions, according to a joint statement.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.